 This is a 2 part, single center study to be conducted in healthy men and women. Part 1 open-label consists of Screening Phase within 28 days before admission into the study center on Day -1, followed by a 3 day treatment period and a follow-up visit on Day 8. A single oral 20 milligram mg dose of rivaroxaban will be administered on Day 1. Pharmacokinetic PK, pharmacodynamics PD, and punch biopsy parameters will be assessed. Part 2 double-blind consists of Screening Phase within 28 days before admission into the study center on Day -1, followed by a 8 day treatment period Day -1 to Day 7 and a follow-up visit on Day 11. Rivaroxaban 20 mg every 12 hrs will be administered on Days 1 through 3 and single 20 mg dose will be given on the morning of Day 4. A single dose of either 4-factor PCC, TXA or saline Placebo will be administered in a randomized, blinded fashion on Day 4. PK, PD, Exploratory Bio-markers and punch biopsy parameters will be assessed. Participants safety will be monitored throughout the study. 